Limosilactobacillus reuteri BIO7251 administration improves metabolic phenotype in obese mice fed a high fat diet: an inter-organ crosstalk between gut, adipose tissue and nervous system

Abstract

Gut microbiota is implicated in the control of host physiology by releasing bioactive actors that could exert a direct or indirect effect on tissue. A dysfunction of the gut microbiota to tissue axis could participate in the development of pathological states such as obesity and diabetes. The aim of this study was to identify the metabolic effect of Limosilactobacillus reuteri (known as Lactobacillus reuteri) BIO7251 (L. reuteri BIO7251) isolated from Corsican clementine orange. Body weight gain, adiposity, glucose tolerance, glucose absorption and food intake were measured in mice fed a high-fat diet in response to a preventive oral administration of L. reuteri BIO7251. This strain of bacteria exerts a beneficial effect on body weight gain by decreasing the subcutaneous adipose tissue mass. The treatment with L. reuteri BIO7251 decreases glucose absorption and food intake in obese/diabetic mice. L. reuteri BIO7251 could be tested as new probiotic strain that could manage body weight during obesity.

Keywords:

• Probiotic
• adipose tissue
• glucose absorption
• hypothalamus

Disclosure statement

PDC and CK were co-founders of Enterosys SAS (France), AA, NP and GA are employed by Enterosys SAS (France), NR is employed by Biodis (France). PDC was co-founder of The Akkermansia company SA and coinventor on patents dealing with gut microbes and health.

Data availability statement

The data presented in this study are available on request from the corresponding author. The data are not publicly available due to the industrial properties of the data.

Additional information

Funding

This research was funded by the company Biodis (doing business as Bioprox Healthcare) with grant funding received in part from BPIfrance for the FRIEND Project (DOS0134630-1/00).